- Lexaria
Bioscience is a company that is passionate about establishing alternatives
to inhalation for rapid-response drug substance delivery in order to
eliminate the lung harm that smoking or vaping may cause
- Lexaria’s
DehydraTECH platform has generated numerous patents with more pending as a
way to provide quick substance delivery to the user’s bloodstream and
better access through the blood-brain barrier
- Lexaria
recently announced it had further improved DehydraTECH, as demonstrated in
testing that showed early pilot-stage human trial participants began to
note edible THC effects in under 10 minutes – more rapidly than the
previous DehydraTECH formulation
- Prior
technology testing has focused on animal subjects and non-psychoactive
products
Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is announcing further
advances in its proprietary oral drug delivery platform DehydraTECH™, which is
innovating edible consumption of nicotine and cannabis products as a
quick-response alternative to inhalation.
Lexaria’s early pilot-stage human trials with
tetrahydrocannabinol (THC) delivery show its newest formulation of
DehydraTECH-enhanced edibles begin providing cannabinoid effectiveness in less
than 10 minutes, which is about twice as fast as traditional DehydraTECH and
four to six times faster than generic industry formulations, according to a
company news release (http://ibn.fm/mwAS9).
Lexaria has been developing DehydraTECH solutions as
alternatives to smoked or vaped drug delivery over the course of the past three
years, establishing a means whereby edible consumption of certain substances
can provide results at rates comparable to inhaled substances and faster than
ingested substances in general.
In June, the company announced that a series of animal
studies showed its DehydraTECH solution could improve on cannabidiol (CBD)
delivery to the blood system by 811 percent and to brain tissue by 1,937
percent when compared with generic medium-chain triglyceride (MCT)
formulations.
The latest announcement marks a new milestone in that the
studies involved humans instead of animals and utilized THC instead of CBD,
demonstrating further potential applications of DehydraTECH technology.
Speed of onset in the use of various drug products is
regarded as a key metric of the products’ potential value, particularly where
pain-relief and the relief of other physical torments are concerned. For
example, nicotine is recognized as a highly addictive substance that can
provoke then alleviate physical withdrawal symptoms or cravings, while certain
cannabis extracts have been promoted in recent years as significant remedies
for pain and muscle spasms or seizure disorders.
Inhalation has traditionally shown the greatest benefit in
terms of rapid-response drug delivery benefits, but Lexaria has been passionate
about delivering alternatives because of the harm substance inhalation can do
to users’ lungs, as demonstrated by the history of smoking tobacco products and
recent concerns about deaths and illnesses linked to vaping cannabis or
nicotine products, which in turn have led health insurers to penalize customers
who smoke or vape products (http://ibn.fm/x5rDh).
Because of DehydraTECH’s rapid-response capabilities,
Lexaria’s technology virtually eliminates a key reason people might risk
sustained injury to their lungs in using tobacco and cannabis products.
Lexaria’s tech works as a complimentary product with other companies’ research
and development on cannabinoids, providing Lexaria a niche as a potential
collaborative team member rather than a competitor as other industry
developments occur.
Lexaria’s position is further strengthened by its worldwide
patents and pending patents for oral or ingestible non-psychoactive
cannabinoids – it has been awarded 16 patents in the United States and
Australia and is awaiting completion of the process for 60 additional patents
in other countries (http://ibn.fm/W46qw).
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
